(Alliance News) - Arecor Therapeutics PLC on Monday said it has entered into a formulation development collaboration with California-based, clinical-stage biotechnology firm, Skye Bioscience Inc, as the pair seek to address the unmet needs in metabolic disease. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Arecor Therapeutics PLC on Tuesday reported a wider loss in 2024, despite an increase in revenue, as the company took a series of impairments related to its decision to refocus its efforts on its insulin candidate. Read More
(Alliance News) - Arecor Therapeutics PLC on Wednesday said it has partnered with an unnamed biopharmaceutical company to develop a novel formulation of peptide therapy. Read More
(Alliance News) - Arecor Therapeutics PLC on Monday said its revenue increased in 2024 and said it is excited by the prospects of its "superior insulin candidate". Read More
Arecor Therapeutics PLC - Cambridgeshire, England-based biopharmaceutical company - Announces the orderly cessation of operations within the Tetris Pharma subsidiary, and a mutual agreement with Xeris BioPharma Holdings Inc to return the group's rights to medication Ogluo. Forms part of the group's strategic review. This concludes that rising supply chain costs and fixed selling prices have significantly reduced margins for Ogluo. In addition, the 2025 revenue outlook for non-Ogluo sales has been materially reduced in light of a partner losing a key NHS tender, materially reducing 2025 revenues for non-Ogluo products. The strategic decision to cease Tetris Pharma operations will enable the group to focus its efforts and resources on opportunities that offer "higher potential for value creation." Read More
Arecor Therapeutics PLC - Cambridgeshire, England-based biopharmaceutical company - Signs licensing agreement for its AT351 liquid drug product with "a wholly owned subsidiary of one of the world's largest independent chemicals marketing companies". Arecor says it receives an undisclosed upfront payment and is eligible for development, regulatory, and commercial milestone payments and royalties on global sales. The licensee receives an exclusive worldwide license and is responsible for all development, regulatory and commercialisation activities. The licensee will pursue approval from the US Food & Drug Administration, with filing expected within three years. Read More
(Alliance News) - Stock prices in London registered a softer open on Monday, with barely a handful of the FTSE 100 in the green, in uninspiring trade as the year draws to a close. Read More
(Alliance News) - London's FTSE 100 is to open lower on Monday, with hawkish Federal Reserve rate expectations keeping a lid on equity market enthusiasm as the year draws to an end. Read More
Arecor Therapeutics PLC - biopharmaceutical company based in Little Chesterford, England - Announces hiring of David Ellam as interim chief financial officer, effective immediately. Ellam was most recently CFO at Sixfold Bioscience Ltd from July 2023 to September this year, before which he worked as a finance strategy consultant for KBio. Prior to this he was CFO at Silence Therapeutics PLC from 2016 to 2019, at Juvenescence Ltd for one year, then at Wondr Medical from June to December 2022. Ellam succeeds Susan Lowther, Arecor's first CFO, who announced her resignation "to pursue new opportunities" in April. Read More
(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - Stock prices in Europe ended lower, starting the week on the back foot ahead of a US inflation reading and Federal Reserve decision, with election results in Europe hogging the spotlight on Monday. Read More
(Alliance News) - Panmure Gordon said the unscheduled trading and funding update from Arecor Therapeutics PLC on Monday highlights a higher working capital requirement than previously expected. Read More
(Alliance News) - Stock prices in London were lower at midday Monday, along with the rest of Europe, as investors digest uncertainty from the latest EU elections. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday. Read More
(Alliance News) - Arecor Therapeutics PLC on Monday said it now expects to require new funding in the third quarter of this year. Read More